

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity

Pharmaxis Ltd

ABN

75 082 811 630

Quarter ended ("current quarter")

31 March 2010

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (Nine months) \$A'000
1.1 Receipts from customers	300	968
1.2 Payments for		
(a) staff costs	(4,056)	(10,511)
(b) advertising and marketing	(155)	(476)
(c) research and development	(6,049)	(19,200)
(d) leased assets	(13)	(28)
(e) other working capital	(2,577)	(5,515)
1.3 Dividends received		
1.4 Interest and other items of a similar nature received	1,003	2,933
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid	(7)	(69)
1.7 Other – Government grants		
Net operating cash flows	(11,554)	(31,898)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (Nine months) \$A'000
1.8 Net operating cash flows (carried forward)	(11,554)	(31,898)
1.9 Cash flows related to investing activities		
Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	(15)	(82)
(d) physical non-current assets	(202)	(2,370)
(e) other non-current assets		
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	2
(e) other non-current assets	-	-
1.11 Loans to other entities		
1.12 Loans repaid by other entities		
1.13 Other (opening cash from acquisition of Topigen Pharmaceuticals Inc)	5,732	5,732
Net investing cash flows	5,515	3,282
1.14 Total operating and investing cash flows	(6,039)	(28,616)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	17	400
1.16 Proceeds from sale of forfeited shares		
1.17 Proceeds from borrowings		
1.18 Repayment of borrowings		
1.19 Dividends paid		
1.20 Other (finance lease payments)	(198)	(892)
Net financing cash flows	(181)	(492)
Net increase (decrease) in cash held	(6,220)	(29,108)
1.21 Cash at beginning of quarter/year to date	102,081	124,993
1.22 Exchange rate adjustments to item 1.21	43	19
1.23 Cash at end of quarter	95,904	95,904

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	71
1.25	Aggregate amount of loans to the parties included in item 1.11	Nil
1.26	Explanation necessary for an understanding of the transactions	
	Payments represent directors fees for quarter	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

As announced to the market on 9 February 2010 Pharmaxis acquired 100% of the shares of Topigen Pharmaceuticals Inc under an agreement whereby Pharmaxis will issue up to 8.2 million ordinary shares based on the achievement of certain research milestones. As at 31 March 2010 2.0 million shares are yet to be issued. Topigen Pharmaceuticals Inc had cash of \$5.7 million at closing.

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Nil

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	Nil	Nil
3.2	Credit standby arrangements	Nil	Nil

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.


	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	2,679	359
4.2 Deposits at call	222	119
4.3 Bank overdraft		
4.4 Other (provide details) – bank accepted bills and term deposits	93,003	101,603
Total: cash at end of quarter (item 1.23)	95,904	102,081

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	Topigen Pharmaceuticals Inc	Nil
5.2 Place of incorporation or registration	Canada	
5.3 Consideration for acquisition or disposal	\$19,722,000	
5.4 Total net tangible assets	\$7,245,000	
5.5 Nature of business	Specialist biopharmaceutical respiratory research company	

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does ~~does not~~* (delete one) give a true and fair view of the matters disclosed.



Sign here:

Date: 14 April 2010
 (Chief Financial Officer/Company Secretary)

Print name: David McGarvey

+ See chapter 19 for defined terms.

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.
 - 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
 - 9.2 - itemised disclosure relating to acquisitions
 - 9.4 - itemised disclosure relating to disposals
 - 12.1(a) - policy for classification of cash items
 - 12.3 - disclosure of restrictions on use of cash
 - 13.1 - comparative information
3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.